Cytek Biosciences, Inc. CTKB Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $204.17M+1.3% | $201.49M+2.4% | $196.83M+0.4% | $196.04M-0.5% | $197.05M-1.7% | ||
| $98.61M+1.6% | $97.03M+5.9% | $91.6M+2.5% | $89.35M+0.6% | $88.8M-0.6% | ||
| $105.56M+1.1% | $104.46M-0.7% | $105.23M-1.4% | $106.68M-1.4% | $108.25M-2.6% | ||
| 51.7%-0.1pp | 51.8%-1.6pp | 53.5%-1.0pp | 54.4%-0.5pp | 54.9%-0.5pp | ||
| $36.35M-0.3% | $36.47M-2.0% | $37.23M-2.4% | $38.16M-3.0% | $39.33M-0.2% | ||
| $48.58M-1.7% | $49.44M+2.6% | $48.18M-1.6% | $48.95M-0.3% | $49.08M-0.1% | ||
| $64.51M+9.4% | $58.94M+14.2% | $51.62M+11.2% | $46.44M+4.1% | $44.6M+3.5% | ||
| $149.43M+3.2% | $144.85M+5.7% | $137.03M+2.6% | $133.54M+0.4% | $133.01M+1.1% | ||
| -$43.87M-8.6% | -$40.39M— | —— | —— | —— | ||
| -21.5%-1.4pp | -20%— | —— | —— | —— | ||
| —— | —— | -$4.73M+7.3% | -$5.11M+5.2% | -$5.39M-2.9% | ||
| $7.93M-24.8% | $10.54M-35.4% | $16.32M-15.5% | $19.3M+14.9% | $16.79M+13.3% | ||
| $38.06M+3.7% | $36.7M+1,476% | -$2.67M-130% | -$1.16M-135% | $3.28M+925% | ||
| -$74M-11.2% | -$66.54M— | —— | —— | —— | ||
| -36.2%-3.2pp | -33%— | —— | —— | —— | ||
| -$0.57-11.8% | -$0.51— | —— | —— | —— | ||
| -$36.3M-10.7% | -$32.81M— | —— | —— | —— | ||
| -17.8%-1.5pp | -16.3%— | —— | —— | —— | ||
| -$43.87M-8.6% | -$40.39M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Cytek Biosciences, Inc.'s revenue?
- Cytek Biosciences, Inc. (CTKB) generated $204.2M in revenue over the trailing twelve months, up 3.6% year over year.
- Is Cytek Biosciences, Inc. profitable?
- Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $74.0M over the trailing twelve months, a -36.2% net margin.
- What are Cytek Biosciences, Inc.'s profit margins?
- Gross margin is 51.7% and operating margin is -21.5%, with a -36.2% net margin.
- What is Cytek Biosciences, Inc.'s earnings per share?
- Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.57.
- Where does Cytek Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
